| 2004N-0214 - Public Information Regulations | |||||||||||||||||||||||
| FDA Comment Number : | EC1 | ||||||||||||||||||||||
| Submitter : | Dr. Paul G King | Date & Time: | 10/12/2004 02:10:34 | ||||||||||||||||||||
| Organization : | FAME Systems | ||||||||||||||||||||||
| Drug Industry | |||||||||||||||||||||||
| Category : | |||||||||||||||||||||||
| Issue Areas/Comments | |||||||||||||||||||||||
| GENERAL | |||||||||||||||||||||||
| GENERAL | |||||||||||||||||||||||
| RE: Docket No. 04N-0214
FORMAL SIGNIFICANT ADVERSE COMMENTS ON:"Public Information Regulations, Direct Final Rule"Pursuant to a ?request for comment? in FEDERAL REGISTER, Vol. 69, No. 1708, pp 53615 ? 53616. BACKGROUND After an initial reading and a rereading of the FDA?s proposed ?Public Information Regulations, Direct Final Rule, and a thoughtful reading of the notice soliciting comment in the Federal Register, FAME Systems offers the "significan adverse comments" in an attached file. Respectfully, Dr. King | |||||||||||||||||||||||